Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.37 |
| ▸ | GABRE | P78334 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9297992 | 0.85 | NQO2 (0.43) | NQO2MAPK1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL2706709 | 0.85 | LMNA (0.47) | LMNANQO2MAPK1ALDH1A1KDM4E | |
| SCHEMBL112719 | 0.83 | KDM4E (0.45) | LMNANQO2MAPK1ALDH1A1KDM4E | |
| SCHEMBL30307699 | 0.83 | KDM4E (0.45) | LMNANQO2MAPK1ALDH1A1KDM4E | |
| SCHEMBL24046189 | 0.81 | NQO2 (0.43) | LMNANQO2MAPK1ALDH1A1KDM4E | |
| SCHEMBL350485 | 0.81 | ALDH1A1 (0.54) | LMNANQO2MAPK1ALDH1A1KDM4E | |
| SCHEMBL1760242 | 0.80 | ALDH1A1 (0.55) | LMNANQO2MAPK1ALDH1A1KDM4E | |
| SCHEMBL1222948 | 0.80 | NQO2 (0.49) | LMNANQO2MAPK1ALDH1A1KDM4E | |
| SCHEMBL15063350 | 0.80 | NQO2 (0.43) | NQO2ALDH1A1SYK | |
| SCHEMBL20223143 | 0.79 | SMN1; SMN2 (0.44) | LMNANQO2MAPK1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370512-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | Cytokinetics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117813296-A | CD38 modulators and methods of use thereof | 赛特凯恩蒂克公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023288195-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | LMNA 1413/4885NQO2 195/4885MAPK1 1424/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | LMNA 589/4885NQO2 1273/4885MAPK1 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.